



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 114 830 A1**

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
11.07.2001 Bulletin 2001/28

(21) Application number: 99943423.6

(22) Date of filing: 20.09.1999

(51) Int Cl.7: **C07K 14/435**, C07K 16/18,  
C12P 21/02, C12P 21/08,  
C12N 15/12

(86) International application number:  
**PCT/JP99/05120**

(87) International publication number:  
**WO 00/17237 (30.03.2000 Gazette 2000/13)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: 18.09.1998 JP 26512698

(71) Applicant: **Japan Science and Technology**  
**Corporation**  
**Kawaguchi-shi, Saitama-ken 332-0012 (JP)**

(72) Inventors:  
• **ENDO, Hitoshi**  
**Sagamihara-shi, Kanagawa-ken 229-0022 (JP)**  
• **SEKINE, Takashi**  
**Tachikawa-shi, Tokyo 190-0003 (JP)**  
• **KUSUHARA, Hiroyuki**  
**Tokyo 113-0022 (JP)**

(74) Representative: **Cresswell, Thomas Anthony et al**  
**J.A. KEMP & CO.**  
**14 South Square**  
**Gray's Inn**  
**London WC1R 5JJ (GB)**

(54) **CEREBRAL ORGANIC ANION TRANSPORTER AND ITS GENE**

(57) A cerebral organic anion transporter OAT3 which is useful as a protein regulating the uptake/excretion of organic anionic substances in the brain; a nucleic

acid having a base sequence encoding the same; and an antibody against the same. The amino acid sequence and the base sequence of the above OAT3 are shown in Sequence Listing in the description.

**EP 1 114 830 A1**

**Description****Technical Field**

- 5   **[0001]** The present invention relates to a gene involved in organic negative ion (organic anion) transport and the polypeptide encoded by the gene.

**Background Art**

- 10   **[0002]** Liver and kidney play important roles in the metabolism and excretion of biologically foreign compounds and drugs out of bodies. Tubule cells and hepatocytes belong to epithelial cells with polarities. It is supposed that some of anionic substances are taken up through the basolateral membranes into kidney and liver by transporters, while the organic anions generated metabolically in cells are excreted by transporters.
- 15   **[0003]** The uptake of organic anions through the basolateral membranes of tubule cells and hepatocytes have been investigated so far in experiment systems using isolated organ perfusion protocols, dissected cells and membrane vesicles. According to such conventional methods, however, the detailed analysis of the transport of organic anions through the basolateral membranes has been difficult. Accordingly, it has been desired to isolate the transporters per se and analyze the properties of transporters in detail.
- 20   **[0004]** Alternatively, plural experimental results suggestively indicate the presence of the transport of organic anions in brain. The transport of organic anions in brain is supposed to function for the extracerebral excretion of endogenous and exogenous organic anions.
- 25   **[0005]** Although the transport of organic anions in brain is speculated to play an important role in the elimination of endogenous anions and foreign compounds from brain, the detail of the transport therein is more ambiguous than the transport in kidney and liver, due to the difficulty in physiological experiments therein.
- 30   **[0006]** Based on these backgrounds, the screening of the organic anion transporter molecules per se has been actively carried out in 1990 and thereafter. Consequently, two organic anion transporters derived from the basolateral membrane of liver have been isolated until the last year. (Hagenbuch, B. et al., Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 10629-33, 1991; Jacquemin, E. et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 133-7, 1994)
- 35   **[0007]** The present inventors independently isolated an organic anion transporter OAT1 responsible for the most important function in the organic anion transport in kidney successfully last year (Sekine, T., et al., J. Biol. Chem., Vol. 272, pp. 18526-9, 1997) and already filed the patent application thereof. OAT1 is a transporter capable of transporting a great number of organic anions with different chemical structures and is also involved in the transport of various anionic drugs. OAT1 is expressed in a specific manner to kidney, while OAT1 is very slightly expressed in brain except kidney.
- 40   **[0008]** Recently, the inventors have further identified a liver-specific organic anion transporter (OAT2) with about 40 % homology to OAT1 in terms of amino acid level (FEBS letter, Vol. 429, pp. 179-182, 1998) (Japanese Patent Application No. 169174/1998).
- 45   **[0009]** The isolation and identification of OAT1 and OAT2 indicates that these organic anion transporters form a family. Additionally because OAT2 is expressed specifically in liver, it is suggested that the family is not kidney-specific but is expressed in various organs.
- 50   **[0010]** As described insofar, it is suggested that an organic anion transport system is present in brain, but the OAT1 expression in brain is quite slight while OAT2 is not present therein. Based on these findings, the inventors have anticipated the presence of an unknown transporter responsible for the organic anion transport in brain.
- 55   **[0011]** Alternatively, the organic anion transport in the basolateral membrane of liver is complicated; particularly, the efflux flow of conjugated substances (many of the conjugated substances are organic anions) generated at a vast scale in hepatocytes into blood has not yet been known. The organic anion transport in liver cannot sufficiently be described on the single basis of the organic anion transporters including OAT2. Hence, the presence of an unknown transporter is suggested.
- 60   **[0012]** The inventors isolated the organic anion transporter OAT1 serving as the most important role in the organic anion transport in kidney (Sekine, T. et al., J. Biol. Chem. Vol. 272, pp. 18526-9, 1997). Based on the structural similarity to OAT1, the inventors identified a liver-specific organic anion transporter (OAT2) (Sekine, T., et al., FEBS letter, Vol. 429, pp. 179-182, 1998). The inventors already reported additionally (Sekine, T., et al., J. Biol. Chem., Vol. 272, pp. 18526-9, 1997) that OAT1 had low homology to an organic cation transporter OCT1 (Grundemann, D. et al., Nature, Vol. 372, pp. 549-52, 1994).
- 65   **[0013]** Taking account of these evidence, the inventors identified a sequence common to OAT1, OAT2 and OCT1 and prepared a degenerate primer based on the sequence. By using the degenerate primer, the inventors identified a novel cDNA fragment with low homology to OAT1, OAT2 and OCT1 from rat brain mRNA by RT (reverse transcript)-PCR (polymerase chain reaction) method. By using the cDNA fragment, a cDNA never reported yet was discriminated

from the rat cDNA library. The resulting protein was designated cerebral type organic anion transporter OAT3 as a third member of the OAT family.

#### Disclosure of the Invention

5

[0014] The invention relates to the organic anion transporter OAT3. The inventive organic anion transporter OAT3 is a transporter with a wide range of substrate selectivity and transports organic anions with different chemical structures (having a potency to take up the organic anions). However, no substantial uptake of a typical organic cation TEA (tetraethylammonium) is observed. Hence, the inventive organic anion transporter OAT3 with a wide range of substrate

10

selectivity is an organic anion transporter with no substantial substrate selectivity of TEA (tetraethylammonium) as the typical organic cation but is selectively distributed in organs mainly including brain and liver.  
[0015] The inventive protein includes the organic anion transporter OAT3 of an amino acid sequence represented by SQ ID No. 2 (in human) or 4 (in rat) or of an amino acid sequence with such a modification of the aforementioned amino acid sequence as deletion, substitution or addition of one or several amino acids. The deletion, substitution or

15

addition of amino acids is satisfactory at an extent such that no organic anion transport activity is deteriorated; the number of the amino acids then is generally 1 to about 110, preferably 1 to about 55. Such protein has generally 60 to 80 %, preferably 70 to 90 % homology in amino acid sequence to the amino acid sequence represented by SQ ID No. 2 or 4.

20

[0016] Furthermore, the invention encompasses a nucleic acid, preferably DNA or RNA, encoding the inventive protein comprising the organic anion transporter OAT3. The inventive nucleic acid encompasses the nucleic acid encoding the inventive protein and nucleic acids hybridizable with the nucleic acid under stringent conditions.

[0017] Still furthermore, the invention relates to a partial sequence of the nucleic acid encoding the inventive protein or nucleotides hybridizable with the partial sequence under stringent conditions.

25

[0018] Still yet furthermore, the invention relates to an antibody against the inventive protein or a polypeptide immunologically identical to the inventive protein.

#### Brief Description of the Drawings

[0019]

30

Fig. 1 depicts the organic anion uptake activity of the inventive rat OAT3 expressed in Xenopus oocyte;

Fig. 2 depicts the results of kinetic analyses of the transport of PAH, estrone sulfate and ochratoxin A with the inventive rat OAT3 in the oocyte;

35

Fig. 3 depicts the results on the inhibition of the organic anion transport with the inventive rat OAT3 by various organic substances;

Fig. 4 depicts the results of the Northern blotting analysis of the inventive rat OAT3 gene;

Fig. 5 depicts the results on the inhibition of the rat OAT3 transport by various metabolites of cerebral type neurotransmitters;

40

Fig. 6 depicts the uptake activity of <sup>14</sup>C-PAH (p-aminohippuric acid) when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 7 depicts the uptake activity of <sup>3</sup>H-estrone sulfate when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 8 depicts the uptake activity of <sup>3</sup>H-dehydroepiandrosterone sulfate when the inventive hOAT3 was expressed in Xenopus oocyte;

45

Fig. 9 depicts the uptake activity of <sup>3</sup>H-ochratoxin A when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 10 depicts the uptake activity of <sup>3</sup>H-cimetidine when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 11 depicts the uptake activity of <sup>3</sup>H-estradiol glucuronide when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 12 depicts the uptake activity of <sup>3</sup>H-prostaglandin E2 when the inventive hOAT3 was expressed in Xenopus oocyte;

50

Fig. 13 depicts the uptake activity of <sup>14</sup>C-taurocholic acid when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 14 depicts the uptake activity of <sup>14</sup>C-glutaric acid when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 15 depicts the uptake activity of <sup>3</sup>H-methotrexate when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 16 depicts the uptake activity of <sup>14</sup>C-salicylic acid when the inventive hOAT3 was expressed in Xenopus oocyte;

55

Fig. 17 depicts the uptake activity of <sup>14</sup>C-indomethacin when the inventive hOAT3 was expressed in Xenopus oocyte;

Fig. 18 depicts the uptake activity of <sup>14</sup>C-cholic acid when the inventive hOAT3 was expressed in Xenopus oocyte; and

Fig. 19 depicts the results on the inhibition of the transport of  $^3\text{H}$ -estrone sulfate with the inventive hOAT3 by various organic substances.

#### Best Mode for Carrying out the Invention

5

**[0020]** The inventive organic anion transporter gene can be isolated and identified by screening of tissues and cells of organs such as kidney and brain in appropriate mammalian animals used as gene sources. The mammalian animals include non-human animals such as dog, cow, horse, goat, sheep, monkey, pig, rabbit, rat and mouse and additionally include human.

10

**[0021]** The gene screening and isolation can preferably be carried out by homology screening and PCR screening. The base sequence of the resulting cDNA is determined by a conventional method; the translation region is analyzed; and the amino acid sequence of the protein encoded by the cDNA, namely the amino acid sequence of OAT3, can be determined.

15

**[0022]** It is verified for example by the following manners that the resulting cDNA is the cDNA of the organic anion transporter gene, namely that the genetic product encoded by the cDNA is the organic anion transporter. More specifically, the cRNA prepared from the isolated OAT3 gene is integrated and expressed in the oocyte; then, the transport (uptake) potency of organic anions in cells is confirmed by assaying the incorporation of an appropriate organic anion as the substrate in cells by the general uptake experiment (Sekine, T., et al., J. Biol. Chem., Vol. 272, pp. 18526-9, 1997).

20

**[0023]** By applying the same uptake experiment to the expression cell, the transport property and substrate specificity of OAT3 can be examined.

**[0024]** The SQ ID No. 3 in the sequence listing shows the base sequence of the cDNA of the rat organic anion transporter OAT3 isolated by such method; and SQ ID No. 4 shows the amino acid sequence thereof.

25

**[0025]** By using the cDNA of the resulting OAT3 gene for screening an appropriate cDNA library or genomic DNA library prepared by using a different gene source, a homologous gene or chromosomal gene derived from a different tissue or a different biological organism or the homology can be isolated.

**[0026]** The base sequence of the cDNA of human organic anion transporter OAT3 identified by such method is shown as SQ ID No. 1 and the amino acid sequence thereof is shown as SQ ID No. 2.

30

**[0027]** By using a synthetic primer designed on the basis of the base sequence as the base sequence (SQ ID No. 1 or 3) of the inventive gene disclosed or a part of the information thereof, the gene can be isolated from the cDNA library by general PCR.

**[0028]** DNA libraries such as cDNA library or genomic DNA library or the like can be prepared by the method described in for example "Molecular Cloning; Sambrook, J., Fritsch, E. F. and Maniatis, T. ed., issued by Cold Spring Harbor Laboratory Press in 1989". Otherwise, any existing commercially available library can satisfactorily be used.

35

**[0029]** The inventive organic anion transporter (OAT3) can be generated by using for example cDNA encoding the organic anion transporter by genetic recombinant technology. For example, DNA (cDNA and the like) encoding the organic anion transporter is integrated in an appropriate expression vector; and the resulting recombinant DNA can then be transfected in an appropriate host cell. The expression system (host vector system) for polypeptide generation includes for example expression systems of bacteria, yeast, insect cells and mammalian cells. Among them, insect cells and mammalian cells are preferably used for the recovery of the functional protein.

40

**[0030]** For the expression of the polypeptide in mammals, for example, the DNA encoding the inventive organic anion transporter is inserted in the downstream of an appropriate promoter (for example, SV40 promoter, LTR promoter, elongation 1 $\alpha$  promoter and the like) in an appropriate expression vector (for example, retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40 vector and the like) to construct an expression vector. By subsequently transforming an appropriate animal cell with the resulting expression vector and culturing the transformant in an appropriate culture medium, the objective polypeptide can be generated. The mammalian cell as the host includes monkey COS-7 cell, Chinese hamster CHO cell, human HeLa cell, or cell lines such as kidney tissue-derived primary culture cell, porcine kidney-derived LLC-PK1 cell and opossum kidney-derived OK cell and the like.

45

**[0031]** As the cDNA encoding the organic anion transporter OAT3, use can be made of cDNA with the base sequence represented by SQ ID No. 1 or 3; as the cDNA, with no specific limitation to the cDNA described above, additionally, DNA corresponding to the amino acid sequence is designed and used, which can encode the polypeptide. In this case, it is known that each amino acid is encoded by one to 6 types of codons, so codons for use can be selected appropriately. For example, a sequence with higher expression can be designed, in terms of the frequency of codons used by a host for expression. DNA with the designed base sequence can be recovered by chemical DNA synthesis, fragmentation and conjugation of the cDNA, and a partial modification of the base sequence. An artificial partial modification of the base sequence or mutagenesis thereof can be carried out by site specific mutagenesis, by utilizing a primer comprising a synthetic oligonucleotide encoding the desired modification "Mark, D. F., et al., Proc. Natl. Acad. Sci. USA, Vol. 8, pp. 5662-5666, 1984".

55

**[0032]** Nucleotides (oligonucleotide or polynucleotide) hybridizable with the inventive organic anion transporter gene

under stringent conditions can be used as probe for detecting the organic anion transporter gene and can also be used for example as antisense oligonucleotide, ribozyme and decoy, so as to modify the expression of the organic anion transporter.

5 **[0033]** In accordance with the invention, the term hybridization under stringent conditions generally means hybridization in 5 x SSC or a hybridization solution at a salt concentration equal to the concentration under a temperature condition of 37 to 42 °C for about 12 hours, followed by preliminary rinsing in 5 x SSC or a solution at a salt concentration equal to the concentration and rinsing in 1 x SSC or at a salt concentration equal to the concentration. Higher stringency can be realized by carrying out rinsing in 0.1 x SSC or a solution at a salt concentration equal to the concentration.

10 **[0034]** Additionally, the invention relates to a partial sequence of the nucleic acid encoding the inventive protein or nucleotides hybridizable with the sequence under stringent conditions. As such nucleotides, generally, use can satisfactorily be made of nucleotides comprising a partial sequence of consecutive 14 or more nucleotides in series in the base sequence represented by SQ ID No. 1 or 3 or a sequence complementary to the partial sequence; so as to enhance the specificity of the hybridization, a longer sequence, for example a sequence of 20 bases or more or a sequence of 30 bases or more, can satisfactorily be used as such partial sequence. These nucleotides can be labeled,

15 if necessary, with radioactive elements, fluorescent substances or chemiluminescent substances.  
**[0035]** The nucleotides comprising a partial sequence of consecutive 14 or more base in series in the inventive base sequence represented by SQ ID No. 1 or 3 or a sequence complementary to the partial sequence preferably carries the specific base sequence of the base sequence encoding the inventive organic anion transporter OAT3 and can satisfactorily be labeled, if necessary.

20 **[0036]** By using the inventive organic anion transporter or a polypeptide immunologically identical thereto, additionally, an antibody can be raised. The antibody can be utilized for detecting or purifying the organic anion transporter. The antibody can be raised, by using the inventive organic anion transporter, a fragment thereof, or a synthetic peptide with a partial sequence thereof or the like as an antigen. The antibody, if polyclonal, can be generated by general methods comprising inoculating such antigen in a host animal (for example, rat and rabbit) and recovering the resulting immunized serum. The antibody, if monoclonal, can be generated by techniques such as general hybridoma method.  
25 Further, the inventive antibody is satisfactorily prepared as chimera form or humanized antibody.

#### Best Mode for Carrying out the Invention

30 **[0037]** The description is now made in more detail in the following examples, but the examples are in no way of limitation of the invention.

**[0038]** In the following examples, the individual procedures followed the methods described in "Molecular Cloning; Sambrook, J., Fritsh, E. F. and Maniatis, T. ed., issued by Cold Spring Harbor Laboratory Press in 1989" or followed the instructions of commercially available kit products if used, unless otherwise stated.

35

#### Example 1

##### Isolation and analysis of multi-selective organic anion transporter 3 (OAT3) cDNA

40 **[0039]** (1) Preparation of degenerate primer based on the base sequence information of OAT1, OAT2 and OCT1  
**[0040]** Based on the base sequence information of OAT1 and OAT2 isolated previously by the inventors and the reported base sequence information of OCT1, degenerate primer was prepared with reference to amino acid sequences in common to these three transporters (amino acids 267-275 and amino acids 447-452 in the amino acid sequence of OAT1).

45 **[0041]** From rat brain was extracted total RNA by GITC method; and poly(A) + RNA was then purified by using an oligodT column. From the rat brain poly(A) + RNA was prepared cDNA by using reverse transcriptase; using the resulting cDNA as template, PCR was conducted with the degenerate primer. Consequently, a PCR product of about 550 bp was prepared.

50 **[0042]** By using a TA cloning kit (manufactured by Invitrogen Co.), the PCR product was cloned; and some of the base sequence was determined. Consequently, a novel cDNA (B10) with homology at the level of 50 % to OAT1 in terms of amino acid level was recovered.

**[0043]** A probe prepared by labeling B10 cDNA with <sup>32</sup>P was used for Northern hybridization with poly(A) + RNA extracted from various rat organs. Positive bands were visually detected in the liver, kidney, brain and eyes.

55 **[0044]** Because the inventors had an excellent cDNA library of rat kidney, the inventors screened the rat kidney cDNA library by using the B10 probe. Hybridization was promoted overnight in a hybridization solution at 37 °C. Thereafter, the filter membrane was rinsed in 0.1 x SSC/0.1 % SDS at 37 °C. As the hybridization solution, use was made of a buffer, pH 6.5 containing 50 % formamide, 5 x standard saline citrate (SSC), 3 x Denhard solution, 0.2 % SDS, 10 % dextran sulfate, 0.2 mg/ml modified salmon sperm DNA, 2.5 mM sodium pyrophosphate, 25 mM MES, and 0.01

% Antifoam B (manufactured by Sigma, Co.). The clone isolated in  $\lambda$ ZipLox was further subcloned in a plasmid vector pZL by in vivo excision method. Consequently, a novel clone (rk1411) with an organic anion transport activity was recovered (Example 2 below is to be referenced concerning transport function analysis).

[0045] The base sequence of the clone (rk1411) recovered above was determined as follows. By firstly using a kilo-sequence deletion kit (manufactured by TaKaRa, Co.), plural plasmid DNAs were prepared by subjecting the clone rk1411 to each deletion of about 300 bp from the single side thereof. The base sequences of the DNAs were determined by using an automatic sequencer (manufactured by Applied BioSystems). Additionally, a specific oligonucleotide primer for rk1411 was prepared; by using the automatic sequencer, the base sequences thereof were also analyzed from the opposite direction. Finally, the whole base sequence of rk1411 was determined. The base sequence is shown as SQ ID No. 3 in the sequence listing. Additionally, the amino acid sequence of the protein is shown as SQ ID No. 4.

#### Example 2 (Identification of the function of rk1411)

##### [0046]

(1) By using T7 RNA polymerase, cRNA (RNA complementary to cDNA) was prepared in vitro from the plasmid carrying the clone (rk1411) as described above (see Sekine, T., et al. J. Biol. Chem., Vol. 272, pp. 18526-9, 1997).

According to the method already reported (Sekine, T., et al. J. Biol. Chem., Vol. 272, pp. 18526-9, 1997), the resulting cRNA was injected in the *Xenopus* oocyte; the oocyte was subjected to an uptake test with various radiolabeled organic anions and organic cations. As shown in Fig. 1, consequently, the oocyte in which rk1411 was expressed could take up  $^{14}\text{C}$ -PAH (p-aminohippuric acid),  $^3\text{H}$ -ochratoxin A and  $^3\text{H}$ -estrone sulfate. Alternatively, the oocyte never transported one typical organic cation  $^{14}\text{C}$ -TEA (tetraethylammonium).

The organic anion transport with rk1411 was subjected to the Michaelis-Menten dynamic test. By examining the change in the uptake of PAH, estrone sulfate and ochratoxin A at various concentrations, the dependency of the rk1411 transport on the concentrations of these substrates was examined. The uptake experiments of radiolabeled PAH, estrone sulfate and ochratoxin A were carried out by using the oocyte injected with rk1411 cRNA according to the method described above. The results are as follows (see Fig. 2): the  $K_m$  values of PAH, estrone sulfate and ochratoxin A were 4.7  $\mu\text{M}$ , 2.3  $\mu\text{M}$  and 0.74  $\mu\text{M}$ , respectively. The results are shown below in Table 1.

Table 1

Results of Michaelis-Menten dynamic test			
	$K_m$ ( $\mu\text{M}$ )	$V_{\text{max}}$ (pmol/hr/oocyte)	$V_{\text{max}}/K_m$ ( $\mu\text{l/hr/oocyte}$ )
PAH	$64.7 \pm 10.0$	$23.3 \pm 2.8$	0.360
Estrone sulfate	$2.34 \pm 0.20$	$7.60 \pm 0.44$	3.24
Ochratoxin A	$0.739 \pm 0.178$	$3.08 \pm 0.33$	4.17

(2) So as to examine the substrate selectivity of rk1411, various anionic substances were added to the  $^3\text{H}$ -estrone sulfate uptake experiment system with the oocyte injected with rk1411 cRNA, to examine their influences (inhibition experiment). The  $^3\text{H}$ -estrone sulfate uptake experiment was conducted by using the oocyte injected with rk1411 cRNA according to the method described above. In the presence and absence of 1 mM each compound (with no label), the uptake of  $^3\text{H}$ -estrone sulfate was assayed. Consequently, various anionic substances (taurocholic acid, cholic acid, bromosulphophthalein, probenecid, indocyanine green, bumetanide, cefoperazone, pyroxicam, furosemide, azidothymidine, benzylpenicillin and the like) significantly inhibited the  $^3\text{H}$ -estrone sulfate transport with rk1411 (see Fig. 3). Meanwhile, cationic substances such as tetraethylammonium, guanidine, quinidine and berapamil never exerted any such inhibitory action (see Fig. 3). The results indicate that rk1411 is a multi-selective transporter and primarily recognizes organic anions. Hence, rk1411 was designated OAT3 (organic anionic transporter 3) as a third member of the OAT family.

#### Example 3

[0047] The expression of the OAT3 gene in individual rat tissues was analyzed (Northern blotting). The OAT3 cDNA in the whole length was labeled with  $^{32}\text{P}$ -dCTP; by using the resulting cDNA as probe, RNAs extracted from various rat tissues were subjected to Northern blotting as follows. 3  $\mu\text{g}$  of poly(A) + RNA was electrophoresed on 1 % agarose/formaldehyde gel and subsequently transferred on a nitrocellulose filter. The filter was hybridized overnight in a hybridization solution containing the whole length of the  $^{32}\text{P}$ -dCTP-labeled OAT3 cDNA at 42  $^{\circ}\text{C}$ . The filter was rinsed in

0.1 x SSC containing 0.1 % SDS at 65 °C.

[0048] The Northern blotting results (see Fig. 4) indicate that a strong band was detected around 2.4 Kb in the RNAs from the kidney, liver and brain. Visually weak expression was also observed in the eyes.

#### 5 Example 4

[0049] Because OAT3 was most strongly expressed in brain among the members of the OAT family, an attempt was made to deduce the role thereof in brain at an inhibition experiment of the OAT3 transport with various metabolites of neurotransmitters (mainly organic anions). As shown in Fig. 5, noradrenalin and serotonin metabolites inhibited the  
10 OAT3 transport of estrone sulfate, suggesting a possibility that these metabolites per se might be substrates of OAT3. The evidence indicates that OAT3 has an action to excrete neurotransmitter metabolites out of brain as one function of cerebral type OAT3.

#### Example 5

15

Isolation and analysis of human-type multi-selective organic anion transporter 3 (OAT3) cDNA

[0050] EST (expressed sequence tag) data base was screened by using the rat OAT3 cDNA isolated previously by the inventors. Human EST clone (H20345) with high homology to the rat OAT3 was identified. A part (333 bp) of the  
20 base sequence of the clone was synthesized by PCR. The cDNA fragment was labeled with <sup>32</sup>P, which was then used as probe for the following screening.

[0051] The human kidney cDNA library maintained by the inventors was subjected to screening with the probe. Hybridization was effected all day long and overnight in a hybridization solution at 37 °C; subsequently, the filter membrane was rinsed in 0.1 x SSC/0.1 % SDS at 37 °C. As the hybridization solution, use was made of a buffer, pH 6.5,  
25 containing 50 % formamide, 5 x SSC (standard saline citrate), 3 x Denhard solution, 0.2 % SDS, 10 % dextran sulfate, 0.2 mg/ml modified salmon sperm DNA, 2.5 mM sodium pyrophosphate, 25 mM MES, and 0.01 % Antifoam B (manufactured by Sigma, Co.). The clone isolated in λZipLox was further subcloned in a plasmid vector pZL by in vitro excision method. Consequently, a novel human organic anion transporter 3 (hOAT3) with an organic anion transport activity was recovered. The analysis of the transport function thereof is described below in Example 6.

[0052] The base sequence of hOAT3 was determined by the following method. Oligonucleotide primers specific to hOAT3 were sequentially synthesized. By using an automatic sequencer (manufactured by Applied BioSystems, Co.), the base sequence was analyzed, starting from both the 5'- and 3'-termini. Finally, the whole base sequence of hOAT3 was determined. The determined base sequence is shown as SQ ID No. 1 in the sequence listing. Based on the cDNA  
30 sequence, the amino acid sequence encoding hOAT3 is described as SQ ID No. 2 in the sequence listing.

[0053] The base sequence of the cDNA is shown in Table 2, while the amino acid sequence is shown in Table 3, in  
35 a corresponding manner.

40

45

50

55

Table 2

## Base sequence of hOAT3 cDNA

5		10	20	30	40	50	60
		CTGAGCTGCC	CTACTACAGC	AGCTGCCGGC	CCCTAGGACA	GAGCAGGGAC	CTCAACTACA
10		70	80	90	100	110	120
		CTGATCACCA	GCGCCATCGG	ATCCAGACCC	GGCCACCAGC	TCTGGCTCGT	CTTGCCCCAG
		130	140	150	160	170	180
		TGCCATGACC	TTCTCGGASA	TCCTGGACCG	TGTGGGAAGC	ATGGGCCATT	TCCAGTTCCT
15		190	200	210	220	230	240
		GCATGTAGCC	ATACTGGGCC	TCCCGATCCT	CAACATGGCC	AACCACAACC	TGCTGCAGAT
		250	260	270	280	290	300
		CTTCACAGCC	GCCACCCCTG	TCCACCACTG	TGCCCCGCC	CACAATGCCT	CCACAGGGCC
20		310	320	330	340	350	360
		TTGGGTGCTC	CCCATGGGCC	CAATGGGAA	GCCTGAGAGG	TGCCTCCGTT	TTGTACATCC
		370	380	390	400	410	420
		GCCCAATGCC	AGCCTGCCCA	ATGACACCCA	GAGGGCCATG	GAGCCATGCC	TGGATGGCTG
25		430	440	450	460	470	480
		GGTCTACAAC	AGCACCAAGG	ACTCCATTGT	GACAGAGTGG	GACTTGGTGT	GCAACTCCAA
		490	500	510	520	530	540
		CAAAGTGAAG	GAGATGGCCC	AGTCTATCTT	CATGGCAGGT	ATACTGATTG	GAGGGCTCGT
30		550	560	570	580	590	600
		GCTTGGAGAC	CTGTCTGACA	GGTTTGGCCG	CAGGCCCATC	CTGACCTGCA	GCTACCTGCT
		610	620	630	640	650	660
		GCTGGCAGCC	AGCGGCTCCG	GTGACGCCCT	CAGCCCCACC	TTCCCCATCT	ACATGGTCTT
35		670	680	690	700	710	720
		CCGCTTCCTG	TGTGGCTTTG	GCACTCTCAG	GATTACCTG	AGCACCGTCA	TCTTGAATGT
		730	740	750	760	770	780
		GGAATGGGTG	CCTACCCGGA	TGCGGGCCAT	CATGTCGACA	GCACTCGGGT	ACTGCTACAC
40		790	800	810	820	830	840
		CTTTGGCCAG	TTCAATCTGC	CCGGCCTGGC	CTACGCCATC	CCCCAGTGGC	GTTGGCTGCA
		850	860	870	880	890	900
		GTTAACTGTG	TCCATTGCCCT	TCTTCGTCTT	CTTCCTATCA	TCCTGGTGGG	CACCAGAGTC
45		910	920	930	940	950	960
		CATACGCTGG	TTGGTCTTGT	CTGGAAGATC	CTCGGAGGCC	CTGAAGATAC	TCCGGCGGGT
		970	980	990	1000	1010	1020
		GGCTGTCTTC	AATGGCAAGA	AGGAAGAGGG	AGAAAGGCTC	AGCTTGGAGG	AGCTCAAACCT
50		1030	1040	1050	1060	1070	1080
		CAACCTGCAG	AAGGAGATCT	CCTTGGCCAA	GCCCAAGTAC	ACCGCAAGTG	ACCTGTTCGG
		1090	1100	1110	1120	1130	1140
		GATACCCATG	CTGCGCCGCA	TGACCTTCTG	TCTTTCCCTG	GCCTGGTTTG	CTACCGGTTT
55							

EP 1 114 830 A1

1150 1160 1170 1180 1190 1200  
TGCCTACTAT AGTTTGGCTA TGGGTGTGGA AGAATTTGGA GTCAACCTCT ACATCCTCCA

5 1210 1220 1230 1240 1250 1260  
SATCATCTTT GGTGGGGTCG ATGTCCCAAG CAAATTCATC ACCATCCTCT CCTTAAGCTA

1270 1280 1290 1300 1310 1320  
CCTGGGGCCGG CATACCACTC AGGCCGCTGC CCTGCTCCTG GCAGGAGGGG CCATCTTGGC

10 1330 1340 1350 1360 1370 1380  
TCTCACCTTT GTGCCCTTGG ACTTGCAGAC CGTGAGGACA GTATTGGCTG TGTTTGGGAA

1390 1400 1410 1420 1430 1440  
GGGATGCCTA TCCAGCTCCT TCAGCTGCCT CTTCTCTAC ACAAGTGAAT TATACCCAC

15 1450 1460 1470 1480 1490 1500  
AGTCATCAGG CAAACAGGTA TGGGCGTAAG TAACCTGTGG ACCCGCTGG SAAGCATGGT

1510 1520 1530 1540 1550 1560  
GTCCCCGCTG GTGAAAATCA CGGGTGAGGT ACAGCCCTTC ATCCCAATA TCATCTACGG

20 1570 1580 1590 1600 1610 1620  
GATCACCGCC CTCCTCGGGG GCAGTGTCTC CTTCTTCCTG CCTGAGAGCC TGAATCAGCC

1630 1640 1650 1660 1670 1680  
CTTGCCAGAG ACTATCGAAG ACCTGGAAAA CTGGTCCCTG CGGGCAAAGA AGCCAAAGCA

25 1690 1700 1710 1720 1730 1740  
GGAGCCAGAG GTGGAAAAGG CCTCCAGAG GATCCCTCTA CAGCCTCAGG GACCAGGCCT

1750 1760 1770 1780 1790 1800  
GGGCTCCAGC TGAGGACAAG GGAACCCCTT TTCCCTGCC TCCAGAGACT GATCCTAGCC

30 1810 1820 1830 1840 1850 1860  
AGGCACCTTA GGAGTATAGG GAGGCCCAT ATAGGTCCAT CCTCCTAGGA TGAAGCCTTC

1870 1880 1890 1900 1910 1920  
TGAGAGCTTG GTGAAGGTGT CTCCATCACC ACCACCAGAG CCTCCTGCC AGCCCTGGCC

35 1930 1940 1950 1960 1970 1980  
AGTTCAAAGG TTCAGCCATC CTTGCCCTTG TTCTCCCTGC AAGCCAGGCC CTGCCATTCT

1990 2000 2010 2020 2030 2040  
TCTGTCTAGC CTTTCCCCAC TGGCCACCTT CCCCCACTGT CCGGTCCTC TTCCCTGAG

40 2050 2060 2070 2080 2090 2100  
GTCCCTGAT ATCCCTGGC TCAGTCTAA CAAGACTGAG TCTTAACAAG ATGAGAAATC

2110 2120 2130 2140 2150 2160  
CTCCCTTCT TGCCTGCCAG ACTTTTCTTT GATGGAAGGT TTCAATAAAC AGCGATAAGA

45 2170 2180 2190 2200 2210 2220  
ACTCTAAAAA AAAAAAAAAA. ....

50

55

Table 3

### Base sequence of hOAT3 amino acid

	Base sequence of HCA15 amino acids																							
5'	ATG	ACC	TTC	TCG	GAG	ATC	CTG	GAC	CST	GTG	GGG	ABC	ATG	GGC	CAT	TTC	CAG	TTC						
10	Met	Thr	Phe	Ser	Glu	Ile	Leu	Asp	Arg	Val	Gly	Ser	Met	Gly	His	Phe	Gln	Phe						
	CTG	CAT	GTA	GCC	ATA	CTG	GGC	CTC	CCG	ATC	CTC	AAC	ATG	GCC	AAC	CAC	AAC	CTG						
15	Leu	His	Val	Ala	Ile	Leu	Gly	Leu	Pro	Ile	Leu	Asn	Met	Ala	Asn	His	Asn	Leu						
	CTG	CAG	ATC	TTC	ACA	GCC	GCC	ACC	CCT	GTG	GAC	CAC	TGT	CGC	CCG	CCC	CAC	AAT						
20	Leu	Gln	Ile	Phe	Thr	Ala	Ala	Thr	Pro	Val	His	His	Cys	Arg	Pro	Pro	His	Asn						
	GCC	TCC	ACA	GGG	CCT	TGG	GTG	CTC	CCC	ATG	GGC	CCA	AAT	GGG	AAG	CCT	GAG	AGG						
25	Ala	Ser	Thr	Gly	Pro	Trp	Val	Leu	Pro	Met	Gly	Pro	Asn	Gly	Lys	Pro	Glu	Arg						
	TGC	CTC	CST	TTT	GTA	CAT	CCG	CCC	AAT	GCC	AGC	CTG	CCC	AAT	GAC	ACC	CAG	AGG						
30	Cys	Leu	Arg	Phe	Val	His	Pro	Pro	Asn	Ala	Ser	Leu	Pro	Asn	Asp	Thr	Gln	Arg						
	GCC	ATG	GAG	CCA	TGC	CTG	GAT	GGC	TGG	GTG	TAC	AAC	AGC	ACC	AAG	GAC	TCC	ATT						
35	Ala	Met	Glu	Pro	Cys	Leu	Asp	Gly	Trp	Val	Tyr	Asn	Ser	Thr	Lys	Asp	Ser	Ile						
	GTG	ACA	GAG	TGG	GAC	TGG	GTG	TGC	AAC	TCC	AAC	AAA	CTG	AAG	GAG	ATG	GCC	CAG						
40	Val	Thr	Glu	Trp	Asp	Leu	Val	Cys	Asn	Ser	Asn	Lys	Leu	Lys	Glu	Met	Ala	Gln						
	TCT	ATC	TTC	ATG	GCA	GGT	ATA	CTG	ATT	GGG	GGG	CTC	GTG	CTT	GGG	GAC	CTG	TCT						
45	Ser	Ile	Phe	Met	Ala	Gly	Ile	Leu	Ile	Gly	Gly	Leu	Val	Leu	Gly	Asp	Leu	Ser						
	GAC	AGG	TTT	GGC	GGC	AGG	CCC	ATC	CTG	ACC	TGC	AGC	TAC	CTG	CTG	CTG	GCA	GCC						
50	Asp	Arg	Phe	Gly	Arg	Arg	Pro	Ile	Leu	Thr	Cys	Ser	Tyr	Leu	Leu	Leu	Ala	Ala						
	AGC	GGC	TCC	GGT	GCA	GCC	TTC	AGC	CGG	ACC	TTC	GGC	ATG	TAC	ATG	GTG	TTC	CSC						
55	Ser	Gly	Ser	Gly	Ala	Ala	Phe	Ser	Pro	Thr	Phe	Pro	Ile	Tyr	Met	Val	Phe	Arg						
	TTC	CTG	TGT	GGC	TTT	GGC	ATC	TCA	GGC	ATT	ACC	CTG	AGC	ACC	GTG	ATC	TTG	AAT						
	Phe	Leu	Cys	Gly	Phe	Gly	Ile	Ser	Gly	Ile	Thr	Leu	Ser	Thr	Val	Ile	Leu	Asn						

EP 1 114 830 A1

	727	736	745	754	763	772
	GTG GAA TGG GTG CCT ACC CGG ATG CGG GCC ATC ATG TCG ACA GCA CTC GGG TAC					
5	Val Glu Trp Val Pro Thr Arg Met Arg Ala Ile Met Ser Thr Ala Leu Gly Tyr					
	781	790	799	808	817	826
	TGC TAC ACC TTT GGC CAG TTC ATT CTG CCC GGC CTG GCC TAC GCC ATC CCC CAG					
10	Cys Tyr Thr Phe Gly Gln Phe Ile Leu Pro Gly Leu Ala Tyr Ala Ile Pro Gln					
	835	844	853	862	871	880
	TGG CGT TGG CTG CAG TTA ACT GTG TCC ATT CCC TTC TTC GTC TTC TTC CTA TCA					
15	Trp Arg Trp Leu Gln Leu Thr Val Ser Ile Pro Phe Phe Val Phe Phe Leu Ser					
	889	898	907	916	925	934
	TCC TGG TGG ACA CCA GAG TCC ATA CGC TGG TTG GTC TTG TCT GGA AAG TCC TCG					
20	Ser Trp Trp Thr Pro Glu Ser Ile Arg Trp Leu Val Leu Ser Gly Lys Ser Ser					
	943	952	961	970	979	988
	GAG GCC CTG AAG ATA CTC CGG CGG GTG GCT GTC TTC AAT GGC AAG AAG GAA GAG					
25	Glu Ala Leu Lys Ile Leu Arg Arg Val Ala Val Phe Asn Gly Lys Lys Glu Glu					
	997	1006	1015	1024	1033	1042
	GGA GAA AGG CTC AGC TTG GAG GAG CTC AAA CTC AAC CTG CAG AAG GAG ATC TCC					
30	Gly Glu Arg Leu Ser Leu Glu Glu Leu Lys Leu Asn Leu Gln Lys Glu Ile Ser					
	1051	1060	1069	1078	1087	1096
	TTG GCC AAG GCC AAG TAC ACC GCA AGT GAC CTG TTC CGG ATA CCC ATG CTG CGC					
35	Leu Ala Lys Ala Lys Tyr Thr Ala Ser Asp Leu Phe Arg Ile Pro Met Leu Arg					
	1105	1114	1123	1132	1141	1150
	CGC ATG ACC TTC TGT CTT TCC CTG GCC TGG TTT GCT ACC GGT TTT GCC TAC TAT					
40	Arg Met Thr Phe Cys Leu Ser Leu Ala Trp Phe Ala Thr Gly Phe Ala Tyr Tyr					
	1159	1168	1177	1186	1195	1204
	AGT TTG GCT ATG GGT GTG GAA GAA TTT GGA GTC AAC CTC TAC ATC CTC CAG ATC					
45	Ser Leu Ala Met Gly Val Glu Glu Phe Gly Val Asn Leu Tyr Ile Leu Gln Ile					
	1213	1222	1231	1240	1249	1258
	ATC TTT GGT GGG GTC GAT GTC CCA GCC AAG TTC ATC ACC ATC CTC TCC TTA AGC					
50	Ile Phe Gly Gly Val Asp Val Pro Ala Lys Phe Ile Thr Ile Leu Ser Leu Ser					
	1267	1276	1285	1294	1303	1312
	TAC CTG GGC CGG CAT ACC ACT CAG GCC GCT GCC CTG CTC CTG GCA GGA GGG GGC					
55	Tyr Leu Gly Arg His Thr Thr Gln Ala Ala Ala Leu Leu Leu Ala Gly Gly Ala					

```

      1321      1330      1339      1348      1357      1366
ATC TTG GCT CTC ACC TTT GTG CCC TTG GAC TTG CAG ACC GTG AGG ACA GTA TTG
5  --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Ile Leu Ala Leu Thr Phe Val Pro Leu Asp Leu Gln Thr Val Arg Thr Val Leu

      1375      1384      1393      1402      1411      1420
GCT GTG TTT GGG AAG GGA TGC CTA TCC AGC TCC TTC AGC TGC CTC TTC CTC TAC
10 --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Ala Val Phe Gly Lys Gly Cys Leu Ser Ser Ser Phe Ser Cys Leu Phe Leu Tyr

      1429      1438      1447      1456      1465      1474
ACA AGT GAA TTA TAC CCC ACA CTC ATC AGG CAA ACA GGT ATG GGC GTA AGT AAC
15 --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Thr Ser Glu Leu Tyr Pro Thr Val Ile Arg Gln Thr Gly Met Gly Val Ser Asn

      1483      1492      1501      1510      1519      1528
CTG TGG ACC GGC GTG GGA AGC ATG GTG TCC CCG CTG GTG AAA ATC ACG GGT GAG
20 --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Leu Trp Thr Arg Val Gly Ser Met Val Ser Pro Leu Val Lys Ile Thr Gly Glu

      1537      1546      1555      1564      1573      1582
GTA CAG CCC TTC ATC CCC AAT ATC ATC TAC GGG ATC ACC GCC CTC CTC GGG GGC
25 --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Val Gln Pro Phe Ile Pro Asn Ile Ile Tyr Gly Ile Thr Ala Leu Leu Gly Gly

      1591      1600      1609      1618      1627      1636
AGT GCT GCC CTC TTC CTG CCT GAG ACC CTG AAT CAG CCC TTG CCA GAG ACT ATC
30 --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Ser Ala Ala Leu Phe Leu Pro Glu Thr Leu Asn Gln Pro Leu Pro Glu Thr Ile

      1645      1654      1663      1672      1681      1690
GAA GAC CTG GAA AAC TGG TCC CTG GGG GCA AAG AAG CCA AAG CAG GAG CCA GAG
35 --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Glu Asp Leu Glu Asn Trp Ser Leu Arg Ala Lys Lys Pro Lys Gln Glu Pro Glu

      1699      1708      1717      1726      1735      1744
GTG GAA AAG GCC TCC CAG AGG ATC CCT CTA CAG CCT CAC GGA CCA GGC CTG GGC
40 --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
Val Glu Lys Ala Ser Gln Arg Ile Pro Leu Gln Pro His Gly Pro Gly Leu Gly

      1753
TCC AGC TGA 3'
40 --- --- ---
Ser Ser ***

```

## Example 6

## Identification of hOAT3 function

[0054] By using T7 RNA polymerase, cRNA (RNA complementary to cDNA) was prepared in vitro from the plasmid comprising the hOAT3 recovered above by the method by Sekine, et al. (see Sekine, T., et al. J. Biol. Chem., Vol. 272, pp. 18526-9, 1997).

[0055] According to the already reported method of Sekine, et al. (Sekine, T., et al. J. Biol. Chem., Vol. 272, pp. 18526-9, 1997), the resulting hOAT3 cRNA was injected in the *Xenopus* oocyte; the oocyte was subjected to an uptake test with various radiolabeled organic anions and organic cations. The control oocyte cell (oocyte cell with no injection of hOAT3 cRNA) and the oocyte cell injected with hOAT3 cRNA were cultured in a buffer containing the following radiolabels for one hour, to assay the uptake of the radiolabels into the oocytes.

[0056] The results are shown in Figs. 6 to 18. In each figure, open column expresses the case of the control oocyte used; and closed column expresses the case of the oocyte injected with hOAT3 cRNA. Fig. 6 depicts the uptake activity of <sup>14</sup>C-PAH (p-aminohippuric acid) (10 μM); Fig. 7 depicts the uptake activity of <sup>3</sup>H- strone sulfate (50 nM); Fig. 8

depicts the uptake activity of  $^3\text{H}$ -dehydroepiandrosterone sulfate (50 nM); Fig. 9 depicts the uptake activity of  $^3\text{H}$ -ochratoxin A (100 nM); Fig. 10 depicts the uptake activity of  $^3\text{H}$ -cimetidine (150 nM); Fig. 11 depicts the uptake activity of  $^3\text{H}$ -estradiol glucuronide (50 nM); Fig. 12 depicts the uptake activity of  $^3\text{H}$ -prostaglandin E2 (1 nM); Fig. 13 depicts the uptake activity of  $^{14}\text{C}$ -taurocholic acid (10  $\mu\text{M}$ ); Fig. 14 depicts the uptake activity of  $^{14}\text{C}$ -glutaric acid (10  $\mu\text{M}$ ); Fig. 15 depicts the uptake activity of  $^3\text{H}$ -methotrexate (100 nM); Fig. 16 depicts the uptake activity of  $^{14}\text{C}$ -salicylic acid (1  $\mu\text{M}$ ); Fig. 17 depicts the uptake activity of  $^{14}\text{C}$ -indomethacin (10  $\mu\text{M}$ ); and Fig. 18 depicts the uptake activity of  $^{14}\text{C}$ -cholic acid (10  $\mu\text{M}$ ).

[0057] As shown in these figures, the values of these radiolabels in the oocyte with hOAT3 expression were higher than the values thereof in the control oocyte, suggesting that hOAT3 transported these compounds.

[0058] Consequently, the oocyte with hOAT3 expression takes up  $^{14}\text{C}$ -PAH (p-aminohippuric acid),  $^3\text{H}$ -estrone sulfate,  $^3\text{H}$ -dehydroepiandrosterone sulfate,  $^3\text{H}$ -ochratoxin A,  $^3\text{H}$ -cimetidine,  $^3\text{H}$ -estradiol glucuronide,  $^3\text{H}$ -prostaglandin E2,  $^{14}\text{C}$ -taurocholic acid,  $^{14}\text{C}$ -glutaric acid,  $^3\text{H}$ -methotrexate,  $^{14}\text{C}$ -salicylic acid,  $^{14}\text{C}$ -indomethacin, and  $^{14}\text{C}$ -cholic acid. On contrast, hOAT3 never transported the typical organic cation  $^{14}\text{C}$ -TEA (tetraethylammonium) (not shown in the figures).

[0059] Then, the hOAT3 transport of organic anions was examined at the Michaelis-Menten kinetic test. By examining the change in the hOAT3 uptake of estrone sulfate and methotrexate at various concentrations, the dependency of the OAT3 transport on the concentrations of these substances was examined. The uptake experiment of radiolabeled estrone sulfate and methotrexate was carried out by using the oocyte injected with hOAT3 cRNA and the control oocyte (with no injection of cRNA), by the method described above. Consequently, the  $K_m$  values of estrone sulfate and methotrexate were 3.08  $\mu\text{M}$  and 2.22  $\mu\text{M}$ , respectively.

[0060] So as to examine the substrate selectivity of hOAT3, various anionic substances were added to the  $^3\text{H}$ -estrone sulfate uptake experiment system with the oocyte injected with hOAT3 cRNA, to examine their influences (inhibition experiment).

[0061] The  $^3\text{H}$ -estrone sulfate uptake experiment was conducted by using the oocyte injected with hOAT3 cRNA according to the method described above.

[0062] More specifically, the control oocyte (oocyte with no injection of hOAT3 cRNA) and the oocyte with injection of hOAT3 cRNA were cultured in a buffer containing 50 nM  $^3\text{H}$ -estrone sulfate alone or containing non-radiolabeled compounds at 500  $\mu\text{M}$  or the concentration shown in the figure for one hour, to assay the uptake of  $^3\text{H}$ -estrone sulfate. When the uptake of 50 nM  $^3\text{H}$ -estrone sulfate singly contained in the buffer into the oocyte with injection of hOAT3 cRNA was designated 100 %, the individual uptake values in the buffer containing inhibitory agents were expressed in %.

[0063] The results are shown in Fig. 19. As shown in Fig. 19, all these compounds inhibited the uptake of  $^3\text{H}$ -estrone sulfate into the oocyte injected with hOAT3 cRNA, indicating that these compounds were interactive with hOAT3. Consequently, it was indicated that various anionic substances (estrone sulfate, PAH, taurocholic acid, probenecid, furosemide, zidovudine, penicillin G, BSP, glutaric acid, indomethacin, and methotrexate) significantly inhibited the transport of  $^3\text{H}$ -estrone sulfate with hOAT3 (see Fig. 19). Alternatively, tetraethylammonium as one of typical organic cations never exerted any inhibitory action. Based on these results, it is evidenced that the inventive hOAT3 is a multi-selective organic anion transporter.

#### Industrial Applicability

[0064] The invention provides a novel organic anion transporter with wide substrate selectivity of organic anions and in selective distribution in brain and liver and the like.

[0065] The inventive organic anion transporter is involved in the uptake of various drugs in cells and is also involved in the dynamics of drugs in biological organisms. Therefore, the inventive organic anion transporter is useful not only for the cell viability and activation but also for the screening of pharmacokinetics.

#### Claims

1. A cerebral type organic anion transporter OAT3.
2. A cerebral type organic anion transporter OAT3 according to claim 1, wherein the cerebral type organic anion transporter OAT3 is of an amino acid sequence represented by SQ ID No. 2 or 4 in the sequence listing or of an amino acid sequence with such a modification of the amino acid sequence represented by SQ ID No. 2 or 4 as deletion of a part of the amino acid sequence, or substitution or addition with other amino acids.
3. A nucleic acid encoding a protein of an amino acid sequence represented by SQ ID No. 2 or 4 in the sequence

# EP 1 114 830 A1

listing or of an amino acid sequence with such a modification of the amino acid sequence represented by SQ ID No. 2 or 4 as deletion of a part of the amino acid sequence, or substitution or addition with other amino acids.

- 5 4. A nucleic acid according to claim 3, wherein the nucleic acid is DNA of a base sequence represented by SQ ID No. 1 or 3 in the sequence listing.
5. A nucleic acid comprising at least 14 consecutive nucleotides in series of the DNA of a base sequence represented by SQ ID No. 1 or 3 or a strand complementary to the 14 consecutive nucleotides in series.
- 10 6. A nucleic acid according to claim 5, wherein the number of the nucleotides is 20 or more.
7. An antibody capable of recognizing a cerebral type organic anion transporter OAT3 according to claim 1 or 2.

15

20

25

30

35

40

45

50

55

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18





Figure 19



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/05120 -

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl<sup>7</sup> C07K14/435, C07K16/18, C12P21/02, C12P21/08, C12N15/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> C07K14/435, C07K16/18, C12P21/02, C12P21/08, C12N15/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, WPI/L, BIOSIS PREVIEW, CAS ONLINE, GenBank/EMBL/DBJ/Geneseq

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	Endou H. et. al., "Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain", J. Biol. Chem. (May, 1999), Vol. 274, No. 19, pages 13675-13680	1-7
A	Endou H. et. al., "Identification of multispecific organic anion transporter 2 expressed predominantly in the liver", FEBS Letters (June, 1998), Vol. 429, pages 179-182	1-7

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not

considered to be of particular relevance

"E" earlier document but published on or after the international filing

date

"L" document which may throw doubts on priority claim(s) or which is

cited to establish the publication date of another citation or other

special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other

means

"P" document published prior to the international filing date but later

than the priority date claimed

"T" later document published after the international filing date or

priority date and not in conflict with the application but cited to

understand the principle or theory underlying the invention

document of particular relevance; the claimed invention cannot be

considered novel or cannot be considered to involve an inventive

step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be

considered to involve an inventive step when the document is

combined with one or more other such documents, such

combination being obvious to a person skilled in the art

document member of the same patent family

"

Date of the actual completion of the international search  
21 December, 1999 (21.12.99)Date of mailing of the international search report  
28 December, 1999 (28.12.99)Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)